Cancer News and Research

Latest Cancer News and Research

FDA grants Priority Review to ImmunoGen’s trastuzumab emtansine BLA

ImmunoGen, Inc., a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Genentech, a member of the Roche Group, has disclosed that the U.S. Food and Drug Administration (FDA) has officially accepted the Biologics License Application (BLA) for trastuzumab emtansine and granted it Priority Review.

7 Nov 2012

FDA approves Pfizer’s XELJANZ to treat rheumatoid arthritis

Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.

6 Nov 2012

Geldanamycin degrades VEGFR2 protein that triggers blood vessel growth

The drug, geldanamycin, is well known for attacking a protein associated with the spread of breast cancer. However, a laboratory-based study found it also degraded a different protein that triggers blood vessel growth.

6 Nov 2012

Pfizer receives FDA approval for Xeljanz to treat rheumatoid arthritis

The U.S. Food and Drug Administration today approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.

6 Nov 2012

Viewpoints: Fight for the Senate will impact GOP effort to void health law; Figuring out insurance is tough even for health economist

For Republicans intent on unraveling President Obama's accomplishments, electing Mitt Romney has been only one part of the equation. Almost as important was installing a Republican majority in the United States Senate, where 50 votes (plus the vice president) would be necessary to repeal much of health care reform, roll back tax increases on the rich and gut social welfare programs. The party's hopes, however, have been severely damaged in recent weeks.

6 Nov 2012

Biologists determine how blind mole rats fight off cancer

Biologists at the University of Rochester have determined how blind mole rats fight off cancer-and the mechanism differs from what they discovered three years ago in another long-lived and cancer-resistant mole rat species, the naked mole rat.

6 Nov 2012

More calories consumed when eating out

Children and adolescents consume more calories and soda and have poorer nutrient-intake on days they eat at either fast-food or full-service restaurants, as compared to days they eat meals at -- or from -- home.

6 Nov 2012

Selective blocking of HDAC11 inhibitor would act exclusively on tumor cells

Several substances inhibiting so-called HDAC enzymes have been studied in trials searching for new anti-cancer drugs in recent years. "Trials have shown that HDAC inhibitors are very effective in arresting growth of cultured cancer cells. But apart from a very rare type of lymphoma, these drugs unfortunately do not clinically affect malignant tumors," says Prof. Dr. Olaf Witt, who heads a research department at DKFZ and is pediatrician at the Center for Child and Adolescent Medicine of Heidelberg University Hospital.

6 Nov 2012

Doctors step up fight for cancer prevention, treatment in developing world

"Doctors were at the forefront of the AIDS treatment revolution a decade ago, denouncing stigmatization and inequality from conference platforms and lobbying politicians alongside the activists," Guardian health editor Sarah Boseley writes in her "Global Health" blog.

6 Nov 2012

Patients with diabetes, multi-vessel coronary artery disease can benefit from bypass surgery

An international, clinical research trial has shown that patients with diabetes whose multi-vessel coronary artery disease is treated with bypass surgery live longer and are less likely to suffer severe complications like heart attacks than those who undergo angioplasty.

6 Nov 2012

Celldex to present results from CDX-301 Phase 1 study in healthy volunteers

Celldex Therapeutics, Inc. today announced an upcoming data presentation at the American Society of Hematology 54th Annual Meeting and Exposition to be held in Atlanta, GA from December 8 through December 11, 2012.

6 Nov 2012

BioMimetic Therapeutics reports net loss of $4.6 million for third quarter 2012

BioMimetic Therapeutics, Inc. today reported its corporate highlights and financial results as of and for the three and nine months ended September 30, 2012. For the three months ended September 30, 2012, the Company reported a net loss of $4.6 million, or $0.16 per diluted share, compared to a net loss of $7.1 million, or $0.25 per diluted share, for the same period in 2011.

6 Nov 2012

Dysregulation of CISTR-ACT causes brachydactyly type E

The patients have single short fingers (metacarpals) and toes (metatarsals) and can be restricted in growth due to a shortened skeleton. This hereditary disease is called brachydactyly type E (Greek for short fingers).

6 Nov 2012

Virttu launches REPLICATE- Open Innovation Forum

Virttu Biologics Limited, a UK biotechnology company with expertise in the field of oncolytic viruses, has announced the launch of the Virttu REPLICATE- Open Innovation Forum.

6 Nov 2012

Inhibition of NOX4 enzyme plays an important role in liver fibrosis

Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) have led a study published in PLoS One showing that the inhibition of a family member of NADPH oxidase enzyme, NOX4, plays an important role in liver fibrosis.

5 Nov 2012

Tengion receives U.S. patent allowance titled ‘Isolated Renal Cells and Uses Thereof’

Tengion, Inc., a leader in regenerative medicine, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 12/617,721, titled "Isolated Renal Cells and Uses Thereof."

5 Nov 2012

No link between daily multivitamin use and reduction of major cardiovascular events in men

In a randomized study that included nearly 15,000 male physicians who were middle-aged or older, daily multivitamin use for more than 10 years of treatment and follow-up did not result in a reduction of major cardiovascular events, heart attack, stroke, or death from cardiovascular disease, according to a study appearing in November 7 issue of JAMA, a theme issue on cardiovascular disease.

5 Nov 2012

Endo, Bioniche decide to end second Urocidin Phase III trial on non-muscle-invasive bladder cancer

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that a second Phase III clinical trial with Urocidin in non-muscle-invasive bladder cancer is being discontinued.

5 Nov 2012

Surgical features determine survival in radical prostatectomy patients

The impact of adjuvant radiotherapy on cancer-specific mortality and overall mortality rates in patients who have undergone radical prostatectomy depends on the cumulative number of certain pathologic features found during surgery, report researchers.

5 Nov 2012

Cervical cancer risk remains high after CIN treatment

Women who undergo treatment for screening-detected cervical intraepithelial neoplasia are more than four times more likely to develop cervical cancer than women with normal smear tests, research suggests.

5 Nov 2012